The Multifaceted Roles of EGFL7 in Cancer and Drug Resistance
SIMPLE SUMMARY: Cancer growth and metastasis require interactions with the extracellular matrix (ECM), which is home to many biomolecules that support the formation of new vessels and cancer growth. One of these biomolecules is epidermal growth factor-like protein-7 (EGFL7). EGFL7 alters cellular ad...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957479/ https://www.ncbi.nlm.nih.gov/pubmed/33804387 http://dx.doi.org/10.3390/cancers13051014 |
_version_ | 1783664657929601024 |
---|---|
author | Heissig, Beate Salama, Yousef Takahashi, Satoshi Okumura, Ko Hattori, Koichi |
author_facet | Heissig, Beate Salama, Yousef Takahashi, Satoshi Okumura, Ko Hattori, Koichi |
author_sort | Heissig, Beate |
collection | PubMed |
description | SIMPLE SUMMARY: Cancer growth and metastasis require interactions with the extracellular matrix (ECM), which is home to many biomolecules that support the formation of new vessels and cancer growth. One of these biomolecules is epidermal growth factor-like protein-7 (EGFL7). EGFL7 alters cellular adhesion to the ECM and migratory behavior of tumor and immune cells contributing to tumor metastasis. EGFL7 is engaged in the formation of new vessels and changes in ECM stiffness. One of its binding partners on the endothelial and cancer cell surface is beta 3 integrin. Beta 3 integrin pathways are under intense investigation in search of new therapies to kill cancer cells. All these properties enable EGFL7 to contribute to drug resistance. In this review, we give insight into recent studies on EGFL7 and its engagement with beta3 integrin, a marker predicting cancer stem cells and drug resistance. ABSTRACT: Invasion of cancer cells into surrounding tissue and the vasculature is an important step for tumor progression and the establishment of distant metastasis. The extracellular matrix (ECM) is home to many biomolecules that support new vessel formation and cancer growth. Endothelial cells release growth factors such as epidermal growth factor-like protein-7 (EGFL7), which contributes to the formation of the tumor vasculature. The signaling axis formed by EGFL7 and one of its receptors, beta 3 integrin, has emerged as a key mediator in the regulation of tumor metastasis and drug resistance. Here we summarize recent studies on the role of the ECM-linked angiocrine factor EGFL7 in primary tumor growth, neoangiogenesis, tumor metastasis by enhancing epithelial-mesenchymal transition, alterations in ECM rigidity, and drug resistance. We discuss its role in cellular adhesion and migration, vascular leakiness, and the anti-cancer response and provide background on its transcriptional regulation. Finally, we discuss its potential as a drug target as an anti-cancer strategy. |
format | Online Article Text |
id | pubmed-7957479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79574792021-03-16 The Multifaceted Roles of EGFL7 in Cancer and Drug Resistance Heissig, Beate Salama, Yousef Takahashi, Satoshi Okumura, Ko Hattori, Koichi Cancers (Basel) Review SIMPLE SUMMARY: Cancer growth and metastasis require interactions with the extracellular matrix (ECM), which is home to many biomolecules that support the formation of new vessels and cancer growth. One of these biomolecules is epidermal growth factor-like protein-7 (EGFL7). EGFL7 alters cellular adhesion to the ECM and migratory behavior of tumor and immune cells contributing to tumor metastasis. EGFL7 is engaged in the formation of new vessels and changes in ECM stiffness. One of its binding partners on the endothelial and cancer cell surface is beta 3 integrin. Beta 3 integrin pathways are under intense investigation in search of new therapies to kill cancer cells. All these properties enable EGFL7 to contribute to drug resistance. In this review, we give insight into recent studies on EGFL7 and its engagement with beta3 integrin, a marker predicting cancer stem cells and drug resistance. ABSTRACT: Invasion of cancer cells into surrounding tissue and the vasculature is an important step for tumor progression and the establishment of distant metastasis. The extracellular matrix (ECM) is home to many biomolecules that support new vessel formation and cancer growth. Endothelial cells release growth factors such as epidermal growth factor-like protein-7 (EGFL7), which contributes to the formation of the tumor vasculature. The signaling axis formed by EGFL7 and one of its receptors, beta 3 integrin, has emerged as a key mediator in the regulation of tumor metastasis and drug resistance. Here we summarize recent studies on the role of the ECM-linked angiocrine factor EGFL7 in primary tumor growth, neoangiogenesis, tumor metastasis by enhancing epithelial-mesenchymal transition, alterations in ECM rigidity, and drug resistance. We discuss its role in cellular adhesion and migration, vascular leakiness, and the anti-cancer response and provide background on its transcriptional regulation. Finally, we discuss its potential as a drug target as an anti-cancer strategy. MDPI 2021-03-01 /pmc/articles/PMC7957479/ /pubmed/33804387 http://dx.doi.org/10.3390/cancers13051014 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Heissig, Beate Salama, Yousef Takahashi, Satoshi Okumura, Ko Hattori, Koichi The Multifaceted Roles of EGFL7 in Cancer and Drug Resistance |
title | The Multifaceted Roles of EGFL7 in Cancer and Drug Resistance |
title_full | The Multifaceted Roles of EGFL7 in Cancer and Drug Resistance |
title_fullStr | The Multifaceted Roles of EGFL7 in Cancer and Drug Resistance |
title_full_unstemmed | The Multifaceted Roles of EGFL7 in Cancer and Drug Resistance |
title_short | The Multifaceted Roles of EGFL7 in Cancer and Drug Resistance |
title_sort | multifaceted roles of egfl7 in cancer and drug resistance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957479/ https://www.ncbi.nlm.nih.gov/pubmed/33804387 http://dx.doi.org/10.3390/cancers13051014 |
work_keys_str_mv | AT heissigbeate themultifacetedrolesofegfl7incanceranddrugresistance AT salamayousef themultifacetedrolesofegfl7incanceranddrugresistance AT takahashisatoshi themultifacetedrolesofegfl7incanceranddrugresistance AT okumurako themultifacetedrolesofegfl7incanceranddrugresistance AT hattorikoichi themultifacetedrolesofegfl7incanceranddrugresistance AT heissigbeate multifacetedrolesofegfl7incanceranddrugresistance AT salamayousef multifacetedrolesofegfl7incanceranddrugresistance AT takahashisatoshi multifacetedrolesofegfl7incanceranddrugresistance AT okumurako multifacetedrolesofegfl7incanceranddrugresistance AT hattorikoichi multifacetedrolesofegfl7incanceranddrugresistance |